Topics

Early lesion detection with F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer.

08:00 EDT 22nd June 2019 | BioPortfolio

Summary of "Early lesion detection with F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer."

Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemically recurrent prostate cancer (BCR), mostly using gallium-68 (Ga)-labelled radiotracers. Alternatively, fluorine-18 (F)-labelled PSMA tracers are available, such as F-DCFPyL, which offer enhanced image quality and therefore potentially increased detection of small metastases. In this study we evaluate the lesion detection efficacy of F-DCFPyL PET/CT in patients with BCR and determine the detection efficacy as a function of their PSA value.

Affiliation

Journal Details

This article was published in the following journal.

Name: European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Pages:

Links

DeepDyve research library

PubMed Articles [35306 Associated PubMed Articles listed on BioPortfolio]

18F-DCFPyL Uptake in an Incidentally Detected Follicular Lymphoma by PET/CT Performed for Biochemically Recurrent Prostate Cancer.

A 75-year-old man, treated with curative intent for histopathologically proven prostate cancer (initial prostate-specific antigen, 27 ng/mL; Gleason 4 + 5 = 9) through external beam radiation therapy ...

Prospective Evaluation of PSMA-Targeted F-DCFPyL PET/CT in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer.

To provide the results of a prospective study evaluating PSMA-targeted F-DCFPyL PET/CT in patients with biochemical failure following radical prostatectomy for prostate cancer (PCa). 31 patients with...

Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted F-DCFPyL PET/CT.

Complete surgical resection of metastatic sites has been shown to prolong survival in select patients with oligometastatic RCC. This treatment strategy is dependent upon the accurate characterization ...

Minimum Number of MRI Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective Lesion-Based Analyses of Patients Treated with Radical Prostatectomy.

To analyze the number of mpMRI targeted biopsy (TBx) cores per lesion needed for PCa detection in patients treated with radical prostatectomy (RP).

Salivary proteins from dysplastic leukoplakia and oral squamous cell carcinoma and their potential for early detection.

Dysplastic leukoplakia (LP) of the oral cavity is a potentially malignant condition for oral squamous cell carcinoma (OSCC), early detection of which remains an unmet clinical need. In an effort to de...

Clinical Trials [7399 Associated Clinical Trials listed on BioPortfolio]

Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.

The objective of this study is to evaluate a radiolabeled urea-based small molecule inhibitor of prostate-specific membrane antigen (PSMA), [18F]DCFPyL (DCFPyL) PET/CT (or PET/MRI imaging ...

Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer

We intend to validate 18F-DCFPyL for imaging patients with metastatic, castrate-resistant PCa (CRPC), so that it may be used to full advantage in supporting existing and emerging therapies...

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

This is a phase II, single-center, open-label, trial to evaluate the diagnostic accuracy of PSMA-targeted 18F-DCFPyL PET/CT for detecting clinically significant prostate cancer in a screen...

PSMA-based 18F-DCFPyL PET/CT: Evaluating Its Application in Real Life

The purpose of the study is to provide pilot data on the clinical situations in which ordering a 18F-DCFPyL positron emission tomography/computed tomography (PET/CT) was thought to be clin...

Integrated 18F-labelled PSMA Project

There are several new therapies available to treat men with advanced prostate cancer; however, the decision making tools needed to determine the best treatment for these patients are notic...

Medical and Biotech [MESH] Definitions

Methods to identify and characterize cancer in the early stages of disease and predict tumor behavior.

Methods to determine in patients the nature of a disease or disorder at its early stage of progression. Generally, early diagnosis improves PROGNOSIS and TREATMENT OUTCOME.

Detection of drugs that have been abused, overused, or misused, including legal and illegal drugs. Urine screening is the usual method of detection.

A form of PERITONITIS seen in patients with TUBERCULOSIS, characterized by lesion either as a miliary form or as a pelvic mass on the peritoneal surfaces. Most patients have ASCITES, abdominal swelling, ABDOMINAL PAIN, and other systemic symptoms such as FEVER; WEIGHT LOSS; and ANEMIA.

Ascertaining of deception through detection of emotional disturbance as manifested by changes in physiologic processes usually using a polygraph.

Quick Search


DeepDyve research library

Relevant Topic

Benign Prostatic Hyperplasia (BPH)
An enlarged prostate (benign prostatic enlargement (BPE) or benign prostatic hyperplasia (BPH)) is common in men after the age of about 50. Having an enlarged prostate does not mean you have cancer. In some cases, an enlarged prostate can cause the ...


Searches Linking to this Article